Palabras clave
herpes
estomatitis herpética
Aciclovir. (Decs Bireme).
Cómo citar
Resumen
El presente artículo reporta un caso clínico de gingivoestomatitis herpética primaria y una breve revisión de los medicamentos usados para tratar la infección por virus del herpes simple (HSV). Se presenta un paciente con múltiples ulceraciones confluentes tanto en la cara ventral como en la dorsal de la lengua y en los labios, compatible con gingivoestomatitis herpética primaria. Esta forma de presentarse las ulceraciones y la edad del paciente son frecuentes en pacientes VIH positivo (Virus de la inmunodeficiencia humana), esto no pudo ser comprobado en el caso ya que el paciente dejo de asistir a consulta luego de recibido el tratamiento. El tratamiento instaurado fue aciclovir tabletas 200 mg cada 6 horas vía oral por 10 días. Cabe mencionar que los tratamientos para el virus del herpes simple con aciclovir no están aprobados por la Administración de Alimentos y Drogas de los Estados Unidos (FDA siglas en inglés) pero si son aceptados por el Centro de Control de Enfermedades (CDC siglas en ingles), también se utilizó gel de polivinilpirrolidona, hialuronato de sodio para facilitar la deglución del paciente. (DUAZARY 2011 No. 2, 199 - 205)Citas
Gandara-Rey JM, Pacheco-Martins JL, Gandara-Vila P, Blanco-Carrion A, Garcia-Garcia A. Primary herpetic gingivostomatitis in a 65-year-old patient. Med Oral. 2002 May-Jun;7(3):180-3.
Arduino PG, Porter SR. Herpes Simplex Virus Type 1 infection: overview on relevant clinico-pathological features. J Oral Pathol Med. 2008 Feb;37(2):107-21.
Amir J, Nussinovitch M, Kleper R, Cohen HA, Varsano I. Primary herpes simplex virus type 1
gingivostomatitis in pediatric personnel. Infection. 1997 Sep-Oct;25(5):310-2.
Fatahzadeh M, Schwartz RA. Human herpes simplex virus infections: epidemiology, pathogenesis,
symptomatology, diagnosis, and management. J Am Acad Dermatol. 2007 Nov;57(5):737-63; quiz 64-6.
Meylan P. [Herpes simplex virus infections, an update for the practitioner]. Rev Med Suisse. 2011 Apr 27;7(292):886-8, 90-3.
Nunes Oda S, Pereira Rde S. Regression of herpes viral infection symptoms using melatonin and SB-73: comparison with Acyclovir. J Pineal Res. 2008 May;44(4):373-8.
zur Hausen H. Herpes simplex virus: benefit versus risk factors in immunization. Dev Biol Stand. 1979;43:373-9
Zheng X, Loutsch JM, Shimomura Y, Gebhardt BM, Hill JM, Kaufman HE. Reactivation of herpes virus after lamellar keratoplasty. Jpn J Ophthalmol. 1999 Jul-Aug;43(4):257-61.
Chauvin PJ, Ajar AH. Acute herpetic gingivostomatitis in adults: a review of 13 cases, including diagnosis and management. J Can Dent Assoc. 2002 Apr;68(4):247- 51.
Amir J, Harel L, Smetana Z, Varsano I. The natural history of primary herpes simplex type 1 gingivostomatitis in children. Pediatr Dermatol. 1999 Jul-Aug; 16 (4):259-63.
Arduino P, Porter S. Oral and perioral herpes simplex virus type I (HSV-I) infection: review of its management*. Oral Diseases. 2006;12:254-70.
Brady RC, Bernstein DI. Treatment of herpes simplex virus infections. Antiviral Res. 2004 Feb;61(2):73-81.
Cernik C, Gallina K, Brodell RT. The treatment of herpes simplex infections: an evidence-based review. Arch Intern Med. 2008 Jun 9;168(11):1137-44.
Alford CA. Acyclovir treatment of herpes simplex virus infections in immunocompromised humans. An overview. Am J Med. 1982 Jul 20;73(1A):225-8.
Leflore S, Anderson PL, Fletcher CV. A risk-benefit evaluation of aciclovir for the treatment and prophylaxis of herpes simplex virus infections. Drug Saf. 2000 Aug;23(2):131-42.
Nikkels AF, Pierard GE. Treatment of mucocutaneous presentations of herpes simplex virus infections. Am J Clin Dermatol. 2002;3(7):475-87.
Emmert DH. Treatment of common cutaneous herpes simplex virus infections. Am Fam Physician. 2000 Mar 15;61(6):1697-706, 708.
Cockerell C. Diagnosis and treatment of cutaneous herpes simplex virus infections. West J Med. 1996 Jun;164(6):518-20.
Zweerink HJ, Stanton LW. Immune response to herpes simplex virus infections: virus-specific antibodies in sera from patients with recurrent facial infections. Infect Immun. 1981 Feb;31(2):624-30.
Nolan A. Interventions for prevention and treatment of herpes simplex virus in cancer patients. Evid Based Dent. 2009;10(4):116-7.
El Hayderi L, Raty L, Failla V, Caucanas M, Paurobally D, Nikkels AF. Severe herpes simplex virus type-I infections after dental procedures. Med Oral Patol Oral Cir Bucal. 222.
Tang JW, Lin M, Chiu L, Koay ES. Viral loads of herpes simplex virus in clinical samples--a 5-year retrospective analysis. J Med Virol. 2010 Nov;82(11):1911-6.
Carrillo C, Prarat M, Vagnozzi A, Calahan JD, Smoliga G, Nelson WM, et al. Specific detection of Rinderpest virus by real-time reverse transcription-PCR in preclinical and clinical samples from experimentally infected cattle. J Clin Microbiol. 2010 Nov;48(11):4094-101.
Thompson C, Whitley R. Neonatal herpes simplex virus infections: where are we now? Adv Exp Med Biol. 2011;697:221-30.
Blevins JY. Primary herpetic gingivostomatitis in young children. Pediatr Nurs. 2003 May-Jun;29(3):199-202.
Tan DH, Kaul R, Raboud JM, Walmsley SL. No impact of oral tenofovir disoproxil fumarate on herpes simplex virus shedding in HIV-infected adults. AIDS. 2011 Jan 14;25(2):207-10.
Amerena VC. Vesiculo-bullous lesions of the oral cavity. Ann R Australas Coll Dent Surg. 1977 Jun;5:101-8.
Slezak R, Buchta V, Forstl M, Prasil P, Sustova Z, Bukac J. [Infections of the oral mucosa caused by herpes simplex virus]. Klin Mikrobiol Infekc Lek. 2009 Aug;15(4):131-7.
Holbrook WP, Gudmundsson GT, Ragnarsson KT. Herpetic gingivostomatitis in otherwise healthy adolescents and young adults. Acta Odontol Scand. 2001 Jun;59(3):113-5.
Tovaru S, Parlatescu I, Tovaru M, Cionca L, Arduino PG. Recurrent intraoral HSV-1 infection: A retrospective study of 58 immunocompetent patients from Eastern Europe. Med Oral Patol Oral Cir Bucal. 2011 Mar;16(2):e163-9.
Amir J. [Primary herpetic gingivostomatitis—clinical aspects and anti-viral treatment]. Harefuah. 2002 Jan;141(1):81-4, 124.
Amir J. Clinical aspects and antiviral therapy in primary herpetic gingivostomatitis. Paediatr Drugs. 2001;3(8):593-7.
Auvin S, Imiela A, Catteau B, Hue V, Martinot A. Paediatric skin disorders encountered in an emergency hospital facility: a prospective study. Acta Derm Venereol. 2004;84(6):451-4.
Birek C. Herpesvirus-induced diseases: oral manifestations and current treatment options. J Calif Dent Assoc. 2000 Dec;28(12):911-21.
Birek C, Ficarra G. The diagnosis and management of oral herpes simplex infection. Curr Infect Dis Rep. 2006 May;8(3):181-8.
Tugizov SM, Webster-Cyriaque JY, Syrianen S, Chattopadyay A, Sroussi H, Zhang L, et al. Mechanisms of viral infections associated with HIV: workshop 2B. Adv Dent Res. 2011 Apr;23(1):130-6.
Tsang CS, Samaranayake LP. Immune reconstitution inflammatory syndrome after highly active antiretroviral therapy: a review. Oral Dis. 2010 Apr;16(3):248-56.
Buchbinder SP. HIV epidemiology and breakthroughs in prevention 30 years into the AIDS epidemic. Top Antivir Med. 2011 May/Jun;19(2):38-46.
Buczynski AK, Castro GF, Leao AT, Souza IP. Impact of oral health on the quality of life of 3-6-years old HIV-infected children. Quality of life in HIV+ children. Eur J Paediatr Dent. 2011 Jun;12(2):81-6.
Safrin S. Treatment of acyclovir-resistant herpes simplex virus infections in patients with AIDS. J Acquir Immune Defic Syndr. 1992;5 Suppl 1:S29-32.
Sepulveda E, Brethauer U, Rojas J, Fernandez E, Le Fort P. Oral ulcers in children under chemotherapy: clinical characteristics and their relation with Herpes Simplex Virus type 1 and Candida albicans. Med Oral Patol Oral Cir Bucal. 2005;10 Suppl 1:E1-8.
Santos LC, Castro GF, de Souza IP, Oliveira RH. Oral manifestations related to immunosuppression degree in HIV-positive children. Braz Dent J. 2001;12(2):135-8.
Fantasia JE, Damm DD. Tongue lesions. Diagnosis: Primary herpetic gingivostomatitis. Gen Dent. 2005 Jan-Feb;53(1):84-5.
Gileva OS, Sazhina MV, Gileva ES, Efimov AV, Scully C. Spectrum of oral manifestations of HIV/AIDS in the Perm region (Russia) and identification of self-induced ulceronecrotic lingual lesions. Med Oral. 2004 May- Jul;9(3):212-5.
Kolokotronis A, Doumas S. Herpes simplex virus infection, with particular reference to the progression and complications of primary herpetic gingivostomatitis. Clin Microbiol Infect. 2006 Mar;12(3):202-11.
Zaun H. [Lesions of the oral mucosa in dermatologic diseases]. Fortschr Med. 1980 May 22;98(19):731-5.
Rogers RS, 3rd. Common lesions of the oral mucosa. A guide to diseases of the lips, cheeks, tongue, and gingivae. Postgrad Med. 1992 May 1;91(6):141-8, 51-3.
Baker DA. The use of antiviral medications in the treatment of herpes simplex virus infections of women. Int J Fertil Womens Med. 1999 Sep-Oct;44(5):227-33.
Shimomura Y. [Herpes simplex virus latency, reactivation, and a new antiviral therapy for herpetic keratitis]. Nihon Ganka Gakkai Zasshi. 2008 Mar;112(3):247-64; discussion 65.
Andrei G, Snoeck R. Emerging drugs for varicellazoster virus infections. Expert Opin Emerg Drugs. 2011 Sep;16(3):507-35.
Curry SS. Cutaneous herpes simplex infections and their treatment. Cutis. 1980 Jul;26(1):41-58.
Pazin GJ, Harger JH. Management of oral and genital herpes simplex virus infections: diagnosis and treatment. Dis Mon. 1986 Dec;32(12):725-824.
Rojas IF, Zepeda MS, Zuniga HP. [Effect of the frequency of maintenance therapy on patients treated for gingivitis and incipient marginal periodontitis]. Rev Dent Chile. 1990 Nov;81(3):124-30.
Tyring SK, Douglas JM, Jr., Corey L, Spruance SL, Esmann J. A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital
herpes infections. The Valaciclovir International Study Group. Arch Dermatol. 1998 Feb;134(2):185-91.
Miller CS, Cunningham LL, Lindroth JE, Avdiushko SA. The efficacy of valacyclovir in preventing recurrent herpes simplex virus infections associated with dental procedures. J Am Dent Assoc. 2004 Sep;135(9):1311-8.
Patel R. Valaciclovir: development, clinical utility and potential. Expert Opin Investig Drugs. 1997 Feb;6(2):173-89.
Almeda J, Casabona J, Allepuz A, Garcia-Alcaide F, del Romero J, Tural C, et al. [Recommendations for non-occupational postexposure HIV prophylaxis. Spanish Working Group on Non-Occupational Postexposure HIV Prophylaxis of the Catalonian Center for Epidemiological Studies on AIDS and the AIDS Study Group]. Enferm Infecc Microbiol Clin. 2002 Oct;20(8):391-400.
Llena Puy MC, Ausina Marquez V. [Analysis of activities of the preventive dentistry service in the Health Area 8 of the Valencia Autonomous Region]. Aten Primaria. 1996 Feb 29;17(3):202-6.
Marci F, Antenucci F, Giannoni M. [Costs of caries therapy and prevention in a school]. Prev Assist Dent. 1989 May-Jun;15(3):31-4.
Mazneikova V, Dimitrova V, Karag’ozova Z, Ivanova M, Mikhailova E, Stefanova A, et al. [Pregnancy with Rhisoimmunization. Results of a retrospective analysis in the maternity hospital “Maichin Dom”]. Akush Ginekol (Sofiia). 2001;40(3):3-7.
Mele G, Loizzi P, Greco P, Gargano G, Varcaccio Garofalo G, Belsanti A. Antibiotic prophylaxis for
abdominal hysterectomy. Clin Exp Obstet Gynecol. 1988;15(4):154-6.
Subirana FX, Lorente J, Perez M, Quesada JL, Grasa J, Fortuny P, et al. [Antibiotic prophylaxis in oncologic pharyngolaryngeal surgery: ceftriaxone versus clindamycin and gentamycin]. Acta Otorrinolaringol Esp. 2001 Mar;52(2):142-5.
Usatine RP, Tinitigan R. Nongenital herpes simplex virus. Am Fam Physician. 2010 Nov 1;82(9):1075-82.
Mubareka S, Leung V, Aoki FY, Vinh DC. Famciclovir: a focus on efficacy and safety. Expert Opin Drug Saf. 2010 Jul;9(4):643-58.
De Clercq E, Andrei G, Balzarini J, Leyssen P, Naesens L, Neyts J, et al. Antiviral potential of a new generation of acyclic nucleoside phosphonates, the 6- [2- (phosphonome thoxy)alkoxy] -2,4- diaminopyrimidines. Nucleosides Nucleotides Nucleic Acids. 2005;24(5-7):331-41.
Hamuy R, Berman B. Treatment of Herpes simplex virus infections with topical antiviral agents. Eur J Dermatol. 1998 Jul-Aug;8(5):310-9.
Lazarus HM, Belanger R, Candoni A, Aoun M, Jurewicz R, Marks L. Intravenous penciclovir for treatment of herpes simplex infections in immunocompromised patients: results of a multicenter, acyclovir-controlled trial. The Penciclovir Immunocompromised Study Group. Antimicrob Agents Chemother. 1999 May;43(5):1192-7.
Schmid-Wendtner MH, Korting HC. Penciclovir cream--improved topical treatment for herpes simplex infections. Skin Pharmacol Physiol. 2004 Sep- Oct;17(5):214-8.
Barton SE, Munday PE, Kinghorn GR, van der Meijden WI, Stolz E, Notowicz A, et al. Topical treatment of recurrent genital herpes simplex virus infections with trisodium phosphonoformate (foscarnet): double blind, placebo controlled, multicentre study. Genitourin Med. 1986 Aug;62(4):247-50.
Javaly K, Wohlfeiler M, Kalayjian R, Klein T, Bryson Y, Grafford K, et al. Treatment of mucocutaneous herpes simplex virus infections unresponsive to acyclovir with topical foscarnet cream in AIDS patients: a phase I/II study. J Acquir Immune Defic Syndr. 1999 Aug 1;21(4):301-6.
Klein RJ. Treatment of experimental latent herpes simplex virus infections with acyclovir and other antiviral compounds. Am J Med. 1982 Jul 20;73(1A):138-42.
Toutous-Trellu L, Hirschel B, Piguet V, Schiffer V, Saurat JH, Pechere M. [Treatment of cutaneous human papilloma virus, poxvirus and herpes simplex virus infections with topical cidofovir in HIV positive patients]. Ann Dermatol Venereol. 2004 May;131(5):445-9.
No se permite un uso comercial de la obra original ni de las posibles obras derivadas, la distribución de las cuales se debe hacer con una licencia igual a la que regula la obra original.